Related Experiment Videos
[Survey of one hundred patients with chronic granulocytic leukemia from the view of recent developments]
Insights
Neutrophil alkaline phosphatase levels and serum cholesterol may indicate CGL phase. High-dose interferon therapy and stem cell transplantation offer improved survival for CGL patients.
Area of Science:
- Hematology
- Oncology
Context:
- Chronic Granulocytic Leukemia (CGL) is a myeloproliferative neoplasm.
- Understanding disease phases and prognostic markers is crucial for treatment decisions.
Purpose:
- To investigate the diagnostic and prognostic significance of neutrophil alkaline phosphatase (NAP) and serum cholesterol in CGL patients.
- To evaluate treatment outcomes, including bone marrow transplantation and interferon therapy.
Summary:
- This study analyzed 100 CGL patients (50 male, 50 female), stratified by disease phase (stable, accelerated).
- Lower serum cholesterol and high NAP scores were observed in the accelerated phase.
- Bone marrow transplantation (BMT) showed improved survival (63+ months) compared to non-transplanted patients (41 months).
Impact:
- Findings suggest NAP and cholesterol levels can aid in CGL phase assessment.
- High-dose interferon therapy is highlighted as a viable alternative to chemotherapy when BMT is contraindicated.
- Autotransplantation using stem cells is a promising therapeutic option.
Abstract:
Data of 100 selected CGL patients were considered. There were 50 male and 50 female patients with an average 38.1 and 41.5 years of age, respectively. Seventy nine patients were in stable, chronic and 21 patients were in accelerated phase. Patients first admitted in blastic phase were excluded. Twenty two patients were subjected to bone marrow transplantation. Characteristically low levels of neutrophil alkaline phosphatase were absent in about 10 to 25% of early cases. It was considered that the level of positive cells could eventually point to the extent of normal population. In the group of the accelerated patients the neutrophil alkaline phosphatase scores were regularly high and the serum cholesterol values lower than those among stable-phase patients. The role of G-CSF (granulocyte colony stimulating factor) was considered. Secondary myelofibrosis was frequently associated with low serum cholesterol. Average survival time was 41 month among non-transplanted and 63+ months among identically-transplanted patients. In accordance with the literature, authors point out that in the presence of any factor not permitting transplantation, prolonged high-dose interferon-therapy could be the first choice, because unlike chemotherapeutic agents used till now, it prolongs survival. Apart from this autotransplantation with marrow or with circulating blood derived stem cells should be considered.